Has Tod Aust received payments from drug or device companies?

Yes. Drug and device makers reported $10,564 in general payments to Tod Aust across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tod Aust did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tod Aust come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tod Aust

Interventional Pain Medicine · Slidell, LANPI 1609191212

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Flowonix Medical Incorporated accounts for 60.1% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2020 at $5,930 and has fallen 95.1% since, to $292 in 2025.

$10,564in general payments, 2019–2025

Across 126 payments — averaging $83.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Flowonix Medical Incorporated$6K
Abbott$2K
Boston Scientific$602
Biotronik NRO, Inc.$145
Carbofix Spine Inc$142
Stryker$125
plus $1K from 31 others

What the payments were for

Consulting fees$5,60053%
Travel & lodging$1,08710%
Food & beverage$3,13130%
Entertainment$7477%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Flowonix Medical Incorporated	2	$6,347
Abbott	41	$2,004
Boston Scientific	15	$602
Biotronik NRO, Inc.	7	$145
Carbofix Spine Inc	1	$142
Stryker	1	$125
Painteq LLC	1	$120
Stimwave Technologies Incorporated	1	$78
Virtus Pharmaceuticals LLC	4	$76
Saluda Medical Americas, Inc.	4	$74
Amgen(2 entities)	4	$66
Arbor Pharmaceuticals, Inc.	4	$58
Si-bone, Inc.	1	$56
Medtronic(2 entities)	3	$55
Tersera Therapeutics LLC	3	$53
Nevro Corp.	2	$52
Avanos Medical	2	$47
AbbVie(2 entities)	3	$44
Collegium Pharmaceutical, Inc.	3	$42
Spinal Simplicity, LLC	2	$40
Nalu Medical, Inc.	2	$36
Bioventus LLC	1	$36
Redhill Biopharma Inc.	2	$32
Sentynl Therapeutics, Inc.	2	$28
MDD US Operations, LLC	2	$27
Scilex Pharmaceuticals Inc.	2	$25
Averitas Pharma Inc.	1	$19
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$17
Pacira Therapeutics, Inc.	1	$17
Daiichi Sankyo Inc.	1	$16
Piramal Critical Care	1	$15
Lundbeck LLC	1	$13
Lilly USA, LLC	1	$13
Biodelivery Sciences International, Inc.	1	$12
Pfizer	1	$11
Forte Bio-pharma LLC	1	$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,564 in reported general payments places this provider in the 75th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024

$116,875

Medicare patients

143

Services billed

1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MovantikNaloxegol Oxalate	47	$20,018
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	674	$19,684
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	526	$8,730
Gabapentin	405	$5,313
Pregabalin	285	$4,426
Lidocaine	64	$4,421
Dronabinol	12	$3,932
Baclofen	135	$3,314
Butorphanol Tartrate	46	$2,277
Oxycodone Hcl	91	$2,257
Cyclobenzaprine Hcl	237	$1,596
Tizanidine Hcl	213	$1,580
Lidocaine-PrilocaineLidocaine/Prilocaine	32	$1,068
Hydromorphone Hcl	52	$659
Ibuprofen	59	$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Redhill Biopharma Inc.Movantik	$32	$20,01847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 interventional pain medicine providers in Louisiana.